Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultrarare disease therapies, has granted 37,975 restricted stock units to 12 newly hired non-executive officers. The awards, approved by the company's compensation committee, were issued under the Ultragenyx Employment Inducement Plan on August 16, 2024. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an employment inducement. The restricted stock units have a four-year vesting schedule, with 25% of the underlying shares vesting annually, contingent on continuous employment with Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), un'azienda biofarmaceutica specializzata nelle terapie per malattie rare e ultrarare, ha concesso 37.975 unità azionarie limitate a 12 nuovi dirigenti non esecutivi. I premi, approvati dal comitato per la compensazione dell'azienda, sono stati emessi ai sensi del Piano di Induzione all'Occupazione Ultragenyx il 16 agosto 2024. Questa concessione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) e funge da incentivo all'occupazione. Le unità azionarie limitate hanno un programma di maturazione di quattro anni, con il 25% delle azioni sottostanti che matura annualmente, a condizione di un'occupazione continua con Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en terapias para enfermedades raras y ultrararas, ha otorgado 37,975 unidades de acciones restringidas a 12 nuevos funcionarios no ejecutivos. Los premios, aprobados por el comité de compensación de la empresa, se emitieron bajo el Plan de Inducción de Empleo de Ultragenyx el 16 de agosto de 2024. Esta concesión se alinea con la Regla de Cotización de Nasdaq 5635(c)(4) y sirve como un incentivo de empleo. Las unidades de acciones restringidas tienen un cronograma de adquisición de cuatro años, con el 25% de las acciones subyacentes que adquieren derechos anualmente, condicionado a la continuidad del empleo con Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), 희귀 및 초희귀 질환 치료에 특화된 생명공학 회사가 37,975개의 제한 주식 단위를 12명의 새로 채용된 비상임 임원에게 부여하였습니다. 보상 위원회에서 승인된 이 상은 Ultragenyx 고용 유인 계획에 따라 2024년 8월 16일에 발급되었습니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 부합하며 고용 유인 역할을 합니다. 제한 주식 단위는 4년의 취득 일정을 가지고 있으며, 기초 주식의 25%가 연간 취득되며, Ultragenyx에서의 지속적인 고용 조건에 따라 달라집니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), une entreprise biopharmaceutique spécialisée dans les thérapies pour les maladies rares et ultrarares, a accordé 37 975 unités d'actions restreintes à 12 nouveaux dirigeants non exécutifs. Les récompenses, approuvées par le comité de rémunération de l'entreprise, ont été émises dans le cadre du Plan d'Induction à l'Emploi Ultragenyx le 16 août 2024. Cette attribution est conforme à la Règle de Cotation Nasdaq 5635(c)(4) et sert d'incitation à l'emploi. Les unités d'actions restreintes ont un calendrier d'acquisition de quatre ans, avec 25 % des actions sous-jacentes acquises chaque année, sous réserve d'un emploi continu avec Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf Therapien für rare und ultrarare Krankheiten spezialisiert hat, hat 37.975 eingeschränkte Aktieneinheiten an 12 neu eingestellte nicht-executive Mitarbeiter vergeben. Die Auszeichnungen, die vom Vergütungsausschuss des Unternehmens genehmigt wurden, wurden im Rahmen des Ultragenyx Employment Inducement Plan am 16. August 2024 vergeben. Diese Vergabe steht im Einklang mit der Nasdaq Listing Rule 5635(c)(4) und dient als Beschäftigungsanreiz. Die eingeschränkten Aktieneinheiten haben einen Vesting-Zeitplan von vier Jahren, wobei 25 % der zugrunde liegenden Aktien jährlich vesten, abhängig von einer kontinuierlichen Beschäftigung bei Ultragenyx.
- Attracting new talent with stock-based compensation
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 37,975 restricted stock units of the company’s common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees?
What is the vesting schedule for the restricted stock units granted by Ultragenyx (RARE)?
Under which plan were the Ultragenyx (RARE) stock grants issued?
What is the purpose of Ultragenyx's (RARE) restricted stock unit grants?
